This is the authors' abstract. We don't add key points for this paper.
XCL1 (lymphotactin), a C-chemokine primarily produced by activated CD8+ T cells, remains poorly characterized in the context of immunotherapy. Here, we conducted comprehensive analyses based on multiple scRNA-seq datasets to identify the presence of XCL1+ CD8+ T cells in hepatocellular carcinoma (HCC) tumor microenvironment. Multiplex Immunohistochemistry and clinical data revealed that the infiltration of this cell population correlated with favorable outcomes. Cell-cell communication demonstrated interactions between XCL1+ CD8+ T cells and NK cells or myeloid cells via CD99 and MIF signaling pathways, respectively. These findings were further supported by spatial transcriptomic data. Using two independent bulk RNA-seq datasets, we found the mean of expression of XCL1 and CD8A could be an independent factor for prognosis of HCC, and next built a prediction score with five marker genes involved in XCL1+ CD8+ T cell population. Our findings proposed that XCL1 may play a key role in anti-tumor immunity and XCL1+ CD8+ T cell population could be a potential target to improve responses for immunotherapy in HCC.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: